Abstract:The pivotal involvement of reverse transcriptase activity in the pathogenesis of the progressive HIV virus has stimulated gradual advancements in drug discovery initiatives spanning three decades. Consequently, nonnucleoside reverse transcriptase inhibitors (NNRTIs) have emerged as a preeminent category of therapeutic agents for HIV management. Academic institutions and pharmaceutical companies have developed numerous NNRTIs, an essential component of antiretroviral therapy. Six NNRTIs have received Food and Drug Administration approval and are widely used in clinical practice, significantly improving the quality of HIV patients. However, the rapid emergence of drug resistance has limited the effectiveness of these medications, underscoring the necessity for perpetual research and development of novel therapeutic alternatives. To supplement the existing literatures on NNRTIs, a comprehensive review has been compiled to synthesize this extensive dataset into a comprehensible format for the medicinal chemistry community. In this review, a thorough investigation and meticulous analysis were conducted on the progressions achieved in NNRTIs within the past 8 years (2016–2023), and the experiences and insights gained in the development of inhibitors with varying chemical structures were also summarized. The provision of a crucial point of reference for the development of wide‐ranging anti‐HIV medications is anticipated.

Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors (2019-2023)

Druggability Modification Strategies of the Diarylpyrimidine‐type Non‐nucleoside Reverse Transcriptase Inhibitors

Lead Optimization of Diarylpyrimidines As Non‐nucleoside Inhibitors of HIV‐1 Reverse Transcriptase

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors

Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.

Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses

Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: from Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs

Electrical and mechanical alternation in pericardial effusion.

Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.

Fragment Hopping-Based Discovery of Novel Sulfinylacetamide-Diarylpyrimidines (dapys) As HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors

[Attitudes to treatment with cytostatic agents. Do cancer patients, physicians, nurses and healthy individuals vary in their views?].

Improving the Anti-Hiv-1 Activity and Solubility of Poorly Water-Soluble DAPYs by Heteroaromatic Replacement Strategy: from Naphthalene-Dapys to Quinoline-Dapys.

Development of Non-Nucleoside Reverse Transcriptase Inhibitors (nnrtis): Our Past Twenty Years

Deciphering the enigmas of non‐nucleoside reverse transcriptase inhibitors (NNRTIs): A medicinal chemistry expedition towards combating HIV drug resistance

Structural Modification of Diarylpyrimidine Derivatives As HIV-1 Reverse Transcriptase Inhibitors

Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs

Chemical space exploration of novel naphthyl-carboxamide-diarylpyrimidine derivatives with potent anti-HIV-1 activity

Discovery of Piperidine‐Linked Pyridine Analogues As Potent Non‐nucleoside HIV‐1 Reverse Transcriptase Inhibitors

Development of Novel Dihydrofuro[3,4- d ]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C

Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.

Structure-guided Design of Novel Biphenyl-Quinazoline Derivatives As Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Improved Anti-Resistance, Selectivity, and Solubility